Yuxin Zhang, Baojun Suo, Xueli Tian, Cailing Li, Xinlu Ren, Kai Zhou, Changmin Mi, Yuxin Wang, Lingling Ma, Liya Zhou, Zhiqiang Song
{"title":"A Review on the Progress and Strategies of <i>Helicobacter pylori</i> Eradication Therapy for Patients With Penicillin Allergy.","authors":"Yuxin Zhang, Baojun Suo, Xueli Tian, Cailing Li, Xinlu Ren, Kai Zhou, Changmin Mi, Yuxin Wang, Lingling Ma, Liya Zhou, Zhiqiang Song","doi":"10.1155/grp/5587248","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong><i>Helicobacter pylori (H. pylori)</i> eradication in penicillin-allergic patients poses a challenge. The currently recommended regimens are inadequate for clinical eradication therapy. Recent years have seen reports of new drugs, regimens, and study evidence in this field; yet comprehensive review articles on the treatment of <i>H. pylori</i> infection in penicillin-allergic patients are scarce.</p><p><strong>Methods: </strong>A literature search of PubMed, Web of Science, Embase, China National Knowledge Infrastructure, the China Science and Technology Journal Database, and the Wanfang Database up to January 10, 2026, was conducted with the search strategy (\"<i>Helicobacter pylori\"</i> OR <i>\"H. pylori</i>\") AND (\"treatment\" OR \"therapy\") AND (\"penicillin\" OR \"beta-lactam\") AND (\"allergy\", \"allergic\" OR \"anaphylaxis\") for both English and Chinese language publications.</p><p><strong>Results: </strong>The final literature review included 132 treatment groups from 56 studies in nine different countries or regions, with a total of 5542 patients included in the analyses. The overall eradication rates of triple regimens were unsatisfactory (72.9%, 95% CI 70.7%-75.2%). The classic quadruple therapy (PPI, bismuth, tetracycline, and metronidazole) is commonly recommended due to its relatively satisfactory efficacy and sufficient research evidence (81.4%, 95% CI 78.6%-84.2%). The mean eradication rate for other regimens containing new drugs such as minocycline, cefuroxime, sitafloxacin, vonoprazan, and rifabutin is well (> 80%).</p><p><strong>Conclusion: </strong>The classical bismuth quadruple therapy used to be the most commonly used regimen. The overall eradication efficacy of triple therapies is unacceptable. Although new drugs and regimens have emerged, their efficacy needs confirmation through more high-quality, large-scale clinical studies to identify the optimal eradication therapy regimen. Individualized treatment, particularly therapies tailored based on the results of genetic antibiotic resistance testing, represents an important direction for future research.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2026 ","pages":"5587248"},"PeriodicalIF":1.6000,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062287/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology Research and Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/grp/5587248","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Helicobacter pylori (H. pylori) eradication in penicillin-allergic patients poses a challenge. The currently recommended regimens are inadequate for clinical eradication therapy. Recent years have seen reports of new drugs, regimens, and study evidence in this field; yet comprehensive review articles on the treatment of H. pylori infection in penicillin-allergic patients are scarce.
Methods: A literature search of PubMed, Web of Science, Embase, China National Knowledge Infrastructure, the China Science and Technology Journal Database, and the Wanfang Database up to January 10, 2026, was conducted with the search strategy ("Helicobacter pylori" OR "H. pylori") AND ("treatment" OR "therapy") AND ("penicillin" OR "beta-lactam") AND ("allergy", "allergic" OR "anaphylaxis") for both English and Chinese language publications.
Results: The final literature review included 132 treatment groups from 56 studies in nine different countries or regions, with a total of 5542 patients included in the analyses. The overall eradication rates of triple regimens were unsatisfactory (72.9%, 95% CI 70.7%-75.2%). The classic quadruple therapy (PPI, bismuth, tetracycline, and metronidazole) is commonly recommended due to its relatively satisfactory efficacy and sufficient research evidence (81.4%, 95% CI 78.6%-84.2%). The mean eradication rate for other regimens containing new drugs such as minocycline, cefuroxime, sitafloxacin, vonoprazan, and rifabutin is well (> 80%).
Conclusion: The classical bismuth quadruple therapy used to be the most commonly used regimen. The overall eradication efficacy of triple therapies is unacceptable. Although new drugs and regimens have emerged, their efficacy needs confirmation through more high-quality, large-scale clinical studies to identify the optimal eradication therapy regimen. Individualized treatment, particularly therapies tailored based on the results of genetic antibiotic resistance testing, represents an important direction for future research.
背景:在青霉素过敏患者中根除幽门螺杆菌(H. pylori)是一个挑战。目前推荐的方案不足以用于临床根除治疗。近年来,在这一领域出现了新的药物、方案和研究证据;然而,关于青霉素过敏患者幽门螺杆菌感染治疗的综合综述文章很少。方法:检索PubMed、Web of Science、Embase、中国国家知识基础设施、中国科技期刊数据库和万方数据库截至2026年1月10日的文献,检索策略为(Helicobacter pylori OR H. pylori)、(treatment OR therapy)、(penicillin OR beta-lactam)、(allergy)、(allergic) OR (anaphylaxis)。结果:最终文献综述纳入了来自9个不同国家或地区的56项研究的132个治疗组,共纳入5542例患者。三联方案的总体根除率不理想(72.9%,95% CI 70.7% ~ 75.2%)。经典的四联疗法(PPI、铋、四环素和甲硝唑)因其相对满意的疗效和充分的研究证据而被普遍推荐(81.4%,95% CI 78.6%-84.2%)。其他含有米诺环素、头孢呋辛、西他沙星、伏诺哌赞和利福布汀等新药的方案的平均根除率很好(约80%)。结论:经典铋四联疗法是最常用的治疗方案。三联疗法的总体根除效果是不可接受的。虽然出现了新的药物和方案,但它们的疗效需要通过更多高质量、大规模的临床研究来确认,以确定最佳的根除治疗方案。个体化治疗,特别是根据基因抗生素耐药性检测结果量身定制的治疗,是未来研究的一个重要方向。
期刊介绍:
Gastroenterology Research and Practice is a peer-reviewed, Open Access journal which publishes original research articles, review articles and clinical studies based on all areas of gastroenterology, hepatology, pancreas and biliary, and related cancers. The journal welcomes submissions on the physiology, pathophysiology, etiology, diagnosis and therapy of gastrointestinal diseases. The aim of the journal is to provide cutting edge research related to the field of gastroenterology, as well as digestive diseases and disorders.
Topics of interest include:
Management of pancreatic diseases
Third space endoscopy
Endoscopic resection
Therapeutic endoscopy
Therapeutic endosonography.